Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CD40 | P25942 | 1/20 | 0.48 |
| ▸ | CD40LG | P29965 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.40 |
| ▸ | FUT8 | Q9BYC5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13880703 | 0.93 | PRMT1 (0.48) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL4991205 | 0.87 | PRMT1 (0.48) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL4991193 | 0.87 | PRMT1 (0.48) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL29959416 | 0.83 | PRMT1 (0.61) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL13880701 | 0.82 | PRMT1 (0.46) | CA2CA3ENPP2PRMT1PRMT3 | |
| SCHEMBL13892241 | 0.82 | ENPP2 (0.46) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL13880666 | 0.81 | ENPP2 (0.49) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL13880652 | 0.81 | ENPP2 (0.47) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL13880599 | 0.81 | ENPP2 (0.46) | CA2CA3CD40CD40LGENPP2 | |
| SCHEMBL10611423 | 0.81 | PRMT1 (0.67) | CA2CA3CD40CD40LGENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098074-A1 | Keratin-Binding Effector Molecules Containing Reactive Dyes | KRT18, KLK3, KLKB1 | CA2 2620/4885CA3 3523/4885CD40 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.